Cerity Partners LLC Sells 5,325 Shares of Bausch Health Cos Inc. (NYSE:BHC)

Cerity Partners LLC trimmed its stake in Bausch Health Cos Inc. (NYSE:BHC) by 6.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 73,535 shares of the company’s stock after selling 5,325 shares during the quarter. Cerity Partners LLC’s holdings in Bausch Health Cos were worth $476,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BHC. Wealthquest Corp acquired a new stake in shares of Bausch Health Cos in the 1st quarter valued at approximately $58,000. Bank of Nova Scotia acquired a new position in shares of Bausch Health Cos during the 4th quarter worth about $83,000. One68 Global Capital LLC bought a new stake in shares of Bausch Health Cos in the 4th quarter valued at about $90,000. Balyasny Asset Management L.P. bought a new stake in shares of Bausch Health Cos in the 4th quarter valued at about $97,000. Finally, Alpine Global Management LLC bought a new position in Bausch Health Cos during the fourth quarter worth about $114,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Trading Down 0.2%

Bausch Health Cos stock opened at $6.77 on Friday. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of -61.50 and a beta of 0.41. The stock’s 50 day moving average is $5.80 and its 200-day moving average is $6.15. Bausch Health Cos Inc. has a 12 month low of $4.25 and a 12 month high of $9.85.

Insiders Place Their Bets

In other Bausch Health Cos news, Director John Paulson purchased 3,564,059 shares of the company’s stock in a transaction dated Friday, June 13th. The stock was bought at an average cost of $5.94 per share, for a total transaction of $21,170,510.46. Following the completion of the transaction, the director owned 32,791,702 shares in the company, valued at approximately $194,782,709.88. This represents a 12.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders have bought 6,352,667 shares of company stock valued at $35,870,767. 8.05% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on BHC shares. Wall Street Zen lowered Bausch Health Cos from a “buy” rating to a “hold” rating in a research note on Saturday, May 10th. Royal Bank Of Canada boosted their target price on Bausch Health Cos from $8.50 to $10.00 and gave the stock a “sector perform” rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $7.38.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.